Wang Xiaofang, Harris Peter C, Somlo Stefan, Batlle Daniel, Torres Vicente E
Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Nephrol Dial Transplant. 2009 Feb;24(2):526-34. doi: 10.1093/ndt/gfn527. Epub 2008 Sep 30.
Antagonists of relevant Gs protein-coupled and agonists of relevant Gi protein-coupled receptors lower renal cAMP and inhibit growth of renal cysts in animal models of human ARPKD (PCK rat) and/or ADPKD (Pkd2(-/WS25) mouse). A calcium-sensing receptor (CaR) is expressed in various tubular segments and couples to Gq, thereby activating phospholipase Cgamma, InsP3 generation and calcium mobilization from intracellular stores, and Gi proteins. By both mechanisms, CaR activation could lower intracellular cAMP and inhibit renal cyst growth.
PCK rat and Pkd2(-/WS25) mouse littermates were fed rodent chow without or with R-568, a type 2 calcimimetic, at a concentration of 0.05% or 0.1% between 3 and 10 or 16 weeks of age. Histomorphometric analysis was performed with Meta-Morph software. Western analysis and immunohistochemical staining were performed using antibodies for aquaporin-2, urea transporter UT-A1 and CaR. Northern blot hybridization was used to quantify the expression of vasopressin V2 receptor and aquaporin 2 mRNAs. Cyclic AMP was measured using an enzyme immunoassay kit.
R-568 had no effect on kidney weight, cyst volume, plasma BUN concentration or severity of the polycystic liver disease. A significant reduction in renal interstitial fibrosis was detected in PCK rats, but not in Pkd2(-/WS25) mice. R-568 administration, as anticipated, resulted in hypocalcemia and hyperphosphatemia, and significant increases in urine output, osmolar clearance, and urinary excretions of sodium, potassium and calcium.
CaR activation had no detectable effect on cystogenesis in models of autosomal recessive or dominant polycystic kidney disease. The lack of protective effect could be due to the absence of CaR in the outer medullary and cortical collecting ducts, the reduction in extracellular calcium and the unaffected levels of renal cAMP and renal expression of cAMP-dependent genes. A possible beneficial effect on interstitial fibrosis deserves further study at more advanced stages of the disease.
在人类常染色体隐性多囊肾病(PCK大鼠)和/或常染色体显性多囊肾病(Pkd2(-/WS25)小鼠)的动物模型中,相关Gs蛋白偶联受体的拮抗剂和相关Gi蛋白偶联受体的激动剂可降低肾内cAMP水平并抑制肾囊肿生长。钙敏感受体(CaR)在多个肾小管节段表达,并与Gq偶联,从而激活磷脂酶Cγ、生成肌醇三磷酸(InsP3)并促使细胞内钙库释放钙,还可与Gi蛋白偶联。通过这两种机制,CaR激活可降低细胞内cAMP水平并抑制肾囊肿生长。
在3至10周龄或16周龄期间,给PCK大鼠和Pkd2(-/WS25)小鼠同窝幼崽喂食不含或含有浓度为0.05%或0.1%的2型钙敏感受体激动剂R-568的啮齿动物饲料。使用Meta-Morph软件进行组织形态计量分析。使用水通道蛋白-2、尿素转运蛋白UT-A1和CaR的抗体进行蛋白质免疫印迹分析和免疫组织化学染色。使用Northern印迹杂交法定量血管加压素V2受体和水通道蛋白2 mRNA的表达。使用酶免疫分析试剂盒测量环磷酸腺苷(cAMP)。
R-568对肾脏重量、囊肿体积、血浆尿素氮浓度或多囊肝病的严重程度没有影响。在PCK大鼠中检测到肾间质纤维化显著减轻,但在Pkd2(-/WS25)小鼠中未检测到。正如预期的那样,给予R-568导致低钙血症和高磷血症,并使尿量、渗透清除率以及钠、钾和钙的尿排泄量显著增加。
在常染色体隐性或显性多囊肾病模型中,CaR激活对囊肿形成没有可检测到的影响。缺乏保护作用可能是由于外髓质和皮质集合管中不存在CaR、细胞外钙减少以及肾内cAMP水平和cAMP依赖性基因的肾表达未受影响。对间质纤维化可能的有益作用值得在疾病更晚期进行进一步研究。